Table 3.

Glycoprotein IIb/IIa trials and outcomes

Trial	Study drug	N	10 endpoints	Outcomes/comments
European Meta-analysis (ISAR-2, ACE, ADMIRAL)	Abciximab Placebo	550 551	Composite of death or re-infarction; up to 3 years of follow-up	Compared with placebo, abciximab ↓ the composite endpoints by 37% (RR = 0.633, P = 0.008) Diabetics versus non-diabetics: ↓ composite endpoints and re-infarction (P = 0.022) No difference in major bleeding
IMPACT-II	Eptifibatide bolus followed by two continous infusions (Bolus 135 ug/kg, infusion 0.5 or 0.75 ug/kg/min ×20–24 h) Placebo	4,010 (total) 1,349 (infusion @ 50) 1,333 (infusion @ 75) 1,328 (placebo)	Composite of death, MI, or urgent target vessel revascularization @ 30 days	Eptifibatide 135/0.5 versus placebo 11.6% versus 9.1%, respectively (P = 0.035) Eptifibatide 135/0.75 versus placebo 11.6% versus 10.0%, respectively (P = NS) No difference in major bleeding in eptifibatide-treated groups
ESPRIT	Double-bolus eptifibatide followed by high-dose infusion Placebo	1,040 (eptifibatide) 1,024 (placebo)	Composite of death, MI, or urgent target vessel revascularization through 6 months	Eptifibatide versus placebo (0.3% versus 0.4%, P = 0.027)
ON-TIME 2	Pre-hospital high-bolus dose tirofiban + DAT + heparin Placebo + DAT + heparin	491 493	Combined incidence of death, recurrent MI, urgent target vessel revascularization, or thrombotic bailout @ 30 days; ST-segment resolution	Tirofiban versus placebo 26% versus 32.9%, respectively (P = 0.02) in STEMI with PCI Lower residual ST-segment deviation 1 h after PCI (P = 0.003) No difference in rates of major bleeding between groups

Abbreviation: N, number of patients.